Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on My Health News Nevada.
Press releases published on June 20, 2025
Safety Shot Provides Update on Expected Closing of Yerbaé Brands Corp. Acquisition
GlobeNewswire
·
June 20, 2025
SCOTTSDALE, AZ, June 20, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”) today provided an update on the expected timing for the closing of its previously announced acquisition of Yerbaé Brands Corp. (TSX-V: YERB. …
Emergent BioSolutions Announces Addition to Russell 3000® Index
GlobeNewswire
·
June 20, 2025
GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the Company will be added to the broad-market Russell 3000® Index, effective after the U.S. market closes on June 27, 2025, as part of the annual …
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
GlobeNewswire
·
June 20, 2025
– If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors – – Decision from European Commission expected in the third quarter of 2025 – STAMFORD, Conn., June 20, 2025 (GLOBE …
PETVIVO HOLDINGS, INC. ANNOUNCES INVESTOR EXERCISE OF PURCHASE OPTION TIED TO SERIES B CONVERTIBLE PREFERRED STOCK OFFERING
GlobeNewswire
·
June 20, 2025
MINNEAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the “Company”) an emerging biomedical device company focused on the …
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
GlobeNewswire
·
June 20, 2025
REDWOOD CITY, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced one oral and six poster presentations …
Telix Precision Medicine Announces AlFluor Radiochemistry Platform
GlobeNewswire
·
June 20, 2025
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces it has launched a novel PET1 radiochemistry solution based on 18F-aluminium fluoride (AlF …
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
GlobeNewswire
·
June 20, 2025
SAN DIEGO and TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat …
Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients
GlobeNewswire
·
June 20, 2025
– Research supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia – – Also highlights that low-cost and off-based EEG/ERP alone also delivered reasonably accurate predictions of cognitive impairment typology …
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)
GlobeNewswire
·
June 20, 2025
LOUISVILLE, Ky., June 20, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Deciphera Pharmaceuticals, LLC for QINLOCK® (ripretinib), which has been approved by the U.S. Food …
GoPath Diagnostics Announces Launch of DiabetesNow: A Genetic Test Panel Designed to Clarify Diabetes Diagnosis
GlobeNewswire
·
June 20, 2025
Buffalo Grove, IL, June 20, 2025 (GLOBE NEWSWIRE) -- A More Complete Genetic View of Diabetes DiabetesNow combines testing for 16 genes associated with monogenic forms of diabetes—including MODY, neonatal, syndromic, and mitochondrial types—with polygenic …
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
GlobeNewswire
·
June 20, 2025
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer’s disease advocacy community …
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
GlobeNewswire
·
June 20, 2025
Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trial European Commission decision expected in August 2025; if approved, resmetirom will be the first medication for people …
Euroopan lääkeviraston ihmislääkekomitealta (CHMP) myönteinen lausunto darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa
GlobeNewswire
·
June 20, 2025
ORION OYJ LEHDISTÖTIEDOTE 20.6.2025 klo 13.30 Euroopan lääkeviraston ihmislääkekomitealta (CHMP) myönteinen lausunto darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa CHMP suosittaa myyntiluvan …
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
GlobeNewswire
·
June 20, 2025
If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2 Recommendation …
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
GlobeNewswire
·
June 20, 2025
TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based therapies for central nervous system injuries, announced …
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
GlobeNewswire
·
June 20, 2025
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating and relapsing rare skin disease affecting …
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
GlobeNewswire
·
June 20, 2025
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo …
Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse
GlobeNewswire
·
June 20, 2025
Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse L’approbation est basée sur des résultats pivots montrant des améliorations de la rémission durable de la maladie et une …
HealthRX Expands Telehealth Website Experience to Include GLP-1 Weight Loss Solutions, Prescription Access, and 24/7 Wellness Support
GlobeNewswire
·
June 20, 2025
BROOKLYN, June 19, 2025 (GLOBE NEWSWIRE) -- HealthRX, a digital health platform serving adults across the United States, has announced an expanded online experience designed to support weight management and long-term wellness through a suite of integrated …
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
GlobeNewswire
·
June 20, 2025
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and two satellite symposia featuring its developmental …